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Recent advances in microsurgery, imaging, and transplantation have led to significant 
refinements in autologous reconstructive options; however, the morbidity of donor sites 
remains. This would be eliminated by successful clinical translation of tissue-engineered 
solutions into surgical practice. Plastic surgeons are uniquely placed to be intrinsically 
involved in the research and development of laboratory engineered tissues and their 
subsequent use. In this article, we present an overview of the field of tissue engineering, 
with the practicing plastic surgeon in mind. The Medical Research Council states that 
regenerative medicine and tissue engineering “holds the promise of revolutionizing 
patient care in the twenty-first century.” The UK government highlighted regenerative 
medicine as one of the key eight great technologies in their industrial strategy worthy 
of significant investment. The long-term aim of successful biomanufacture to repair 
composite defects depends on interdisciplinary collaboration between cell biologists, 
material scientists, engineers, and associated medical specialties; however currently, 
there is a current lack of coordination in the field as a whole. Barriers to translation are 
deep rooted at the basic science level, manifested by a lack of consensus on the ideal cell 
source, scaffold, molecular cues, and environment and manufacturing strategy. There is 
also insufficient understanding of the long-term safety and durability of tissue-engineered 
constructs. This review aims to highlight that individualized approaches to the field are 
not adequate, and research collaboratives will be essential to bring together differing 
areas of expertise to expedite future clinical translation. The use of tissue engineering 
in reconstructive surgery would result in a paradigm shift but it is important to maintain 
realistic expectations. It is generally accepted that it takes 20–30 years from the start of 
basic science research to clinical utility, demonstrated by contemporary treatments such 
as bone marrow transplantation. Although great advances have been made in the tissue 
engineering field, we highlight the barriers that need to be overcome before we see the 
routine use of tissue-engineered solutions.
Keywords: tissue engineering, regenerative medicine, stem cells, translation, bioengineering, barriers to 
translation, translational research, plastic and reconstructive surgery
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iNTRODUCTiON
Reconstructive plastic surgery aims to provide living tissue in 
order to restore both form and function following a wide range 
of congenital or acquired defects. Operations are complex, often 
transcending anatomic boundaries. Versatility resulting from 
surgery on a full range of tissues including skin, fat, nerve, mus-
cle, bone, and cartilage promotes innovation, and with the recent 
advances in medical imaging (1), microsurgery (2), vascularized 
composite allotransplantation (3, 4), nanotechnology (5), cell 
biology, biomaterials (6), and 3D printing (7–10), treatment 
options for patients are wider than ever before. Even armed with 
new reconstructive options based on microsurgical principles and 
transplantation, surgeons have become increasingly cognizant 
that there is the real potential for a paradigm shift in reconstruc-
tive surgery in the medium term via tissue-engineered solutions. 
The implementation into practice could potentially eliminate the 
need for donor sites and their morbidity, reduce hospital stay and 
associated costs (11).
Relevance of This Article
Contrary to public perception, the diverse workload of recon-
structive plastic surgeons comprises a relatively small proportion 
of purely esthetic procedures (12). The majority of operations 
undertaken pertain to neoplasia and wound management, 
with a significant health economic impact (12). Over one mil-
lion patients are treated per year in NHS England by Plastic 
Surgeons (13, 14), with evidence suggesting that this workload 
will continue to increase (15). If you extrapolate these figures 
worldwide, it is easy to see the clinical need is vast. As a group, 
reconstructive surgeons are facing more challenging composite 
defects than ever before coupled with Internet and media savvy 
patients with increasing expectations (16). Technological innova-
tion in reconstructive surgery in the twentieth century offered the 
possibility for surgeons to operate on microvascular structures 
enabling free tissue transfers (2) and extremity replantations. 
Despite these developments in practice, we are still confronted 
with shortcomings relating to the availability of donor tissues. 
In order to overcome this, novel approaches have been investi-
gated. Among these approaches, the most attractive concept is 
tissue engineering.
Tissue engineering is a modern, interdisciplinary field com-
bining principles of engineering, physics, and the life sciences. 
It shares a common objective with plastic and reconstructive 
surgery; “to restore form and function” (17, 18). The long-term 
aim of tissue engineering is to biomanufacture autologous, vas-
cularized, physiologically relevant solutions to repair and restore 
complex defects. Successful biomanufacture will depend on the 
correct blend of cell source, suitable scaffold and ideal microen-
vironment (19). Answers to these fundamental questions rely on 
interdisciplinary collaboration between cell biologists, material 
scientists, biotechnologists, and associated medical specialties 
(20). Upscaling and widespread use in health services will need 
close interaction with the cell therapy industry and associated 
manufacturers.
The surgical community worldwide is becoming increasingly 
aware of the research landscape. The American Society of Plastic 
surgeons have highlighted the role of tissue engineering in the 
future of plastic surgery (21), particularly the need for a focus 
on translation from bench research to clinical practice. In the 
United Kingdom, the House of Lords recognized the potential 
of regenerative medicine to impact on the health service and 
highlighted the current “lack of coordination” in the field as a 
whole (22, 23). Recommendations included the development of 
multidisciplinary working groups (basic scientists, clinicians, 
investors, manufacturing experts, and regulators), as well as 
governmental support to drive forward the agenda on regenera-
tive medicine.
There is a need to develop NHS capacity with regional facili-
ties licensed for Good Laboratory Practice (GLP) and current 
Good Manufacturing Practices (cGMP), which are engaged 
with a clinical specialty skilled in the manipulation of cells and 
the viable insertion of tissue-engineered constructs. Skilled in 
vascularization and in tissue viability/transfer, plastic surgeons 
already fulfill this role as an interface specialty delivering complex 
reconstructive techniques to a broad range of other specialties. 
The regional service structure of plastic surgery within the NHS 
would further support their capacity to align with regional cGMP 
facilities and deliver tissue-engineering solutions to a range of 
medical and surgical specialties.
Objectives
Assess the Shortcomings Of
Traditional Reconstructive Options
Up till now, restoration of form and function has relied on the use 
of autologous (rarely allogeneic) tissue, alloplastic implants, or a 
combination of the two. Although effective, these options have 
disadvantages that merit highlighting (Table 1).
Tissue-Engineered Solutions
Although tissue-engineered solutions hold great promise, we 
must be realistic in that contemporary tissue-engineered con-
structs implanted into immune-competent animal models have 
been observed to undergo inflammation, fibrosis, foreign body 
reaction, and degradation (Table 1; Figure 1). One of the major 
problems remains vascularization of larger volume constructs 
(24), and an issue coming to the fore in modern literature is the 
potential for tumorigenesis (25).
Provide an Overview Of
Fundamental Principles of Tissue Engineering: Cell Source, 
Scaffold, Assembly Method, and Molecular and Mechanical 
Signaling
We discuss the multiple considerations for tissue engineer-
ing research in order to highlight the complexity of the field 
as a whole. This supports the argument for multidisciplinary 
coordination, which is required to take the field forward. The 
fundamental principles are summarized in Figure 2: cell source, 
scaffolds, assembly method, subsequent growth (molecular 
and mechanical signaling), and patient safety. These factors all 
contribute to the “environment” (19). In simple terms, the cell is 
required for synthesis of the new tissue matrix, while the scaffold, 
biomolecules, and the microenvironment provide trophic cues to 
guide proliferation and differentiation. Growth, induction, and 
TAble 1 | Advantages and shortcomings of reconstructive solutions for managing tissue defects.
Reconstructive solution Advantages Disadvantages
Autologous •	 No immunological complications
•	 No ethical constraints
•	 Biologically compatible
•	 Minimal degradation
•	 Fewer legal restrictions
•	 No disease transmission
•	 Challenging harvesting cells in aged or diseased
•	 Donor site morbidity
•	 Limited quantity of tissue available
•	 Two separate operative sites—greater risk and cost
Allogeneic •	 No donor site morbidity
•	 Donor cells may have higher viability
•	 Tissue always healthy
•	 Greater quantity of available tissue
•	 Temporary (i.e., cadaveric skin used in extensive burns)
•	 Tissue typing is required
•	 Immunosuppression may be needed
•	 Risk of disease transmission
•	 Greater legal hurdles
•	 Ethical and psychological challenges
Synthetic •	 Maintain structural integrity
•	 Predictable and reproducible physical and mechanical 
properties
•	 Cost effective
•	 Avoids concerns over disease transmission
•	 Extrusion
•	 Infection
•	 Cannot restore all of specialized tissue/organ functions
•	 Do not respond to biological cues/grow with patient
•	 May provoke an immune/inflammatory/fibrotic reaction
•	 Materials safety testing and manufacturing governance
Tissue engineered •	 Biocompatible
•	 Good biofunctionality
•	 Good retention of size and shape
•	 No donor site morbidity
•	 Unlimited expansion of cells/tissues
•	 No immunological concerns
•	 Mechanical stability
•	 Long-term effect unknown
•	 Size often limited by vascularity
•	 Costly
•	 Tumorigenic potential
•	 Difficult to engineer “physiologically relevant/mature tissue”
FigURe 1 | Shortcomings of nasal and auricular cartilage tissue engineering.
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FigURe 3 | Advantages and disadvantages of different cell sources utilized in tissue engineering.
FigURe 2 | Considerations in the field of tissue engineering.
4
Al-Himdani et al. Tissue-Engineering in Plastic and Reconstructive Surgery
Frontiers in Surgery | www.frontiersin.org February 2017 | Volume 4 | Article 4
FigURe 4 | Hierarchy of stem cells highlighting different degrees of potency. Yamanaka factors are used to induce differentiated cells to become pluripotent.
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maintenance of maturation are important for providing durabil-
ity of the tissue-engineered construct.
Cell Sources
Classical tissue-engineering approaches use tissue-derived 
cells (not necessarily stem cells) seeded onto scaffolds (36). 
These cells may be autologous, allogenic, or xenogenic cells; 
however, autologous cells are the preferred choice due to the 
lack of immunogenicity. Cells may be further classified based 
on differences in their differentiating capabilities (Figure  3). 
Adult somatic cells are fully differentiated, and therefore have 
restricted future differentiation potential and relatively poor 
growth, limiting their usefulness for tissue-engineering purposes 
(37). Progenitor cells are more differentiated than stem cells and 
are therefore referred to as multipotent rather than pluripotent 
(38). Stem cells are non-differentiated cells, able to proliferate 
through multiple generations and differentiate into a variety of 
cell types (39, 40), and may overcome the limitations of differ-
entiated cells (36) when used for tissue engineering. Pluripotent 
by definition, stem cells can be derived from embryonic, fetal, 
or adult (or postnatal somatic) tissue (39). Stem cells are the 
current preferred cell source for tissue-engineering endeavors 
and regenerative medicine therapies due to their high potency 
and capacity for expansion (41). Contemporary research efforts 
have focused on adult stem cells or progenitor cells for tissue-
engineering purposes. The use of embryonic and fetal tissue, 
although providing pluripotent stem cells with high proliferative 
potential, raises potential ethical issues as well as safety concerns 
over tumorigenic potential (42, 43). Adult derived stem cells, 
which are found among differentiated cells, have been isolated 
from an increasingly varied number of tissues over the past 
decade such as bone marrow (i.e., mesenchymal stem cells and 
hematopoietic stem cells), adipose [adipose-derived stem cells 
(44)], epithelial (epithelial-derived stem cells), and umbilical 
cord (cord blood stem cells) tissue (43). Developments made in 
isolation and culture of adult derived stem cells have improved 
cell yield during harvest. Subsequent research has focused on 
manipulating proliferation and differentiation into the desired 
cell type (45). Adult derived stem cells can only divide a finite 
number of times and accumulate genetic changes that can limit 
their supply for tissue-engineering purposes. The discovery 
of induced pluripotent stem cells (iPSCs) by Takahashi and 
Yamanaka (46) introduced the idea that a mature differentiated 
cell could be reverted to a state of pluripotency and multilineage 
potential (Figure 4). While this process, which has been shown 
to be possible with human cells, creates a potentially limitless 
source of easily accessible stem cells, it is not without draw-
backs (47). Reprograming the cells has raised questions about 
FigURe 5 | Advanced technologies for monitoring cell behavior and survival. (A) ICELLigence impedance based cell assay machine. (b) Proliferation curves 
at different cell seeding densities generated by iCELLigence. (C) The Renishaw inVia confocal Raman microscope allows identification of stem cells based on the 
scattering of photons due to vibrations of molecular bonds. (D) Seahorse XFe24 Extracellular Flux Analyzer is used for measurement of cellular bioenergetics.
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epigenetic effects in particular, with a number of papers purport-
ing to show DNA errors that have arisen during the process of 
inducing pluripotency (47, 48). Questions have also been raised 
regarding immunogenicity of engineered tissues with iPSCs 
implanted into a genetically identical mouse able to provoke an 
unexpected T cell-mediated immune response (49).
To better understand the behavior of specific cell types 
and their utility for tissue-engineering purposes, there is an 
increased reliance on advanced technologies (41) to monitor cell 
phenotype, migration, proliferation, migration, and differentia-
tion both in  vitro and in  vivo. Impedance-based systems such 
as iCELLigence system (ACEA Biosciences) as well as Seahorse 
XFe24 Extracellular Flux Analyzer are allowing real-time 
monitoring of cellular processes and offer distinct and impor-
tant advantages over traditional endpoint assays (Figure  5). 
Contemporary imaging modalities such as two photon excited 
fluorescence microscopy (50) and Raman spectroscopy (51), 
both with high resolution and depth of penetration (>100 nm, 
300 nm and 1 mm, 0.4 mm, respectively) are giving research-
ers clearer insights into the behavior of different cell types 
(Figure  5).
Further complications arise from the wide donor-to-donor 
variation in the behavior of cells, particularly stem cell popula-
tions, that has become apparent. Human adipose-derived stem 
cells, an increasingly prevalent source of adult stem cells for 
studies in tissue engineering, exhibit high donor-to-donor 
variability with regard to proliferation and differentiation char-
acteristics, and this is not explained simply by donor age (52).
Currently, there is no consensus on the ideal cell source for 
tissue-engineering purposes. A thorough understanding of the 
advantages and disadvantages of each cell type is crucial to decide 
on cell selection and the optimal culture conditions in order to 
engineer specific tissue types.
Scaffold Choices
An appropriate scaffold is crucial to any tissue-engineering 
strategy. The ideal scaffold provides a framework for cell growth 
and development, allowing cells to attach, migrate, proliferate, 
and differentiate while facilitating cellular reorganization into a 
functional 3D network (Table 2).
Desirable characteristics of scaffolds include the following:
•	 Biomimetic (53)
•	 Biodegradable (with site specific absorption kinetics) (54–56)
•	 Appropriate mechanical strength
•	 Optimal micropores: enabling vascularization and allowing 
metabolic needs to be met (oxygen and waste product transfer)
•	 Biocompatible (57)
•	 Non-immunogenic (58)
•	 Versatile with regard to manufacturing methods
•	 Functionalization potential (59)
TAble 2 | Advantages and disadvantages of biomaterials utilized currently as scaffolds in tissue engineering.
Scoffold 
class
Scoffold subtype Macrostructure Microstructure Chemical  
composition
Advantages Disadvantages
Synthetic Polylactic acid (PLA) •	 More predictable and 
reproducible mechanical and 
physical properties
•	 High tensile strength, 
degradation rate, and elastic 
modulus (7)
•	 More readily available
•	 Relatively inexpensive
•	 Immune reaction
•	 Lack biological cues (8)
•	 Toxicity
•	 Infections
Polyglycolic acid (PGA)
Polyethylene glycol  
derivatives (PEG)
Biological Fibrin •	 Biocompatibility
•	 Cell-controlled degradability
•	 Intrinsic cellular interaction
•	 Hydrated environment
•	 Non-toxic
•	 Mucoadhesive
•	 Cytocompatible (9)
•	 Batch variations
•	 Limited range of mechanical 
properties
•	 Less reproducible
•	 Costly
•	 Specific processing conditions (10)
Elastin
Collagen
(Continued )
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•	 3D control of macroarchitecture
•	 Various nano- and micro-topographies, stiffnesses, and micro-
environments appropriate to the proliferation, migration, and 
maturation of native or engrafted cells
•	 Suitable for clinical grade sterilization
•	 Suitable for industrial production.
Scaffolds are generally classified as biological (organic) or 
synthetic (inorganic). Engineering of the cell-scaffold construct 
can be undertaken in vitro in a bioreactor or in vivo by implanting 
the construct into the body. Advances in engineering, material 
science, and biomanufacturing technologies have enabled the 
design and development of more complex scaffolds using self 
assembly (60), computer modeling, bioprinting, and nano-
technology (60–62). “Functionalized,” “decorated,” or “smart” 
biomaterials that incorporate of biomolecular moieties on the 
surface, aim to orchestrate, and optimize the attachment and 
growth of cells and the synthesis of new tissue (61, 63). Scaffold 
size is largely limited by the lack of effective vascularization. 
Most successful work in the field focuses on understanding 
native tissue constituents and microarchitecture to allow accurate 
reproduction of functional tissue (64).
Environment
Consideration of the biophysiochemical 3D environment is 
crucial for tissue engineering. Cells not only require a scaffold for 
structural and biological support but also require an environment 
that provides the correct combination of growth supplements, 
differentiation signals, perfusion of nutrients, gaseous/waste 
exchange, pH regulation, and mechanical forces. The metabolic 
requirements of different tissues are varied and dictate the perfu-
sion, gaseous/waste exchange, pH, and mechanical environment 
required. There is an increasing awareness that molecular and 
mechanical signaling is pivotal in the growth and differentiation 
of tissue-engineered constructs, and in addition to well-known 
growth factors such as bone morphogenetic proteins, vascular 
epithelial growth factor, basic fibroblast growth factor FGF-2, and 
transforming growth factor-β (65), “induction factors,” including 
oxygen tension (66–68), mechanical (69), and electrical stimula-
tion (70), guide subsequent proliferation and differentiation of 
cells. Cells participate in a web of multidirectional interactions 
within their niches and tissues of residence [interacting with 
various nanotopographically sized cues (71)]. This has implica-
tions during biomimetic tissue engineering, where the cellular 
environment (biomolecules), scaffold topography, and other 
external factors (mechanical and electrical stimulation) require 
regulation. This is complicated by the fact that cells not only 
respond to multiple stimuli but also have a direct impact on the 
environment themselves.
Research in this field is at the interface of cell biologists, 
engineers, materials scientists, and clinicians and is expanding 
rapidly. Multidisciplinary teams are working on bioreactor tech-
nology, which is vital for in  vitro tissue engineering. Optimal 
conditions can to a great extent be applied and controlled 
through the use of bioreactors to mimic required conditions 
(72), and specialized bioreactors to help engineer a range of tis-
sues have been developed in recent years (73, 74). Bioreactors are 
FigURe 6 | Different environmental stimuli and the fundamental components of bioreactor technology.
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increasingly being used to provide more complex environments, 
exposing cells to a range of controllable electrical, electromag-
netic, biomolecular, and mechanical cues while varying cell–cell 
or cell–matrix interactions (Figure 6) (73).
CURReNT bARRieRS TO TRANSlATiON
Tissue engineering has the potential for major clinical impact in 
plastic and reconstructive surgery. Some products using tissue-
engineering concepts are already on the market; however, the 
panacea of functional vascularized composite tissue-engineered 
constructs is still theoretical. Translation of good basic sci-
ence research from the laboratory to clinical reality remains a 
considerable challenge (Figure  7). In addition to meeting the 
scientific challenges of engineering durable and functional tissue 
for implantation into patients (75), one must also navigate the 
complex regulatory processes. The regulations controlling the 
delivery of stem cell therapeutics to the clinic parallel many 
of those developed for the pharmaceutical industry (76, 77). 
Guidelines governing the development of cell-based products can 
be found on websites for the U.S. Food and Drug Administration 
(FDA),1 the European Medicines Agency,2 and related govern-
mental regulatory authorities. The United States Pharmacopeia 
is an internationally recognized resource defining the currently 
accepted industry standards for product purity, potency, and 
quality assurance.3 These targets are hard to meet outside a large, 
1 http://www.fda.gov/.
2 http://www.ema.europa.eu/ema.
3 http://www.usp.org/.
FigURe 7 | barriers to translation in tissue engineering.
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TAble 3 | Successful applications of tissue-engineered constructs in humans.
Organ/
tissue
No. of 
patients
Cell source Outcomes Reference
Bladder 7 Bladder urothelial and muscle 
cells
Improved volume and compliance with no metabolic consequences at mean 46 months 
follow-up
Atala et al. (84)
Trachea 1 Recipient MSCs Functional airway with a normal appearance and mechanical properties at 4 months Macchiarini et al. (85)
Urethra 5 Muscle and epithelial cells Maintenance of wide urethral calibers without strictures, normal architecture on biopsy at 
3 months following implantation
Raya-Rivera 
et al. (87)
Nasal 
cartilage
5 Autologous nasal 
chondrocytes
Good structural stability and respiratory function after 1 year Fulco et al. (88)
Vaginal 
organs
4 Vulval biopsy—epithelial and 
muscle cells
Tri-layered structure on biopsy with phenotypically normal smooth muscle and epithelia 
with follow-up up to 8 years
Raya-Rivera 
et al. (90)
well-equipped commercial enterprise. Many research laborato-
ries attached to clinical facilities do not produce mesenchymal 
stem cells in accordance with the criteria for either GLP or the 
more stringent cGMP, both requiring strict operational and 
certification records relating to all laboratory equipment and 
reagents used in the cell manufacture process (1, 4, 5).
A clear understanding of the manufacturing workflow is 
required to allow autologous and allogeneic tissue-engineered 
product integration into clinical practice (78). Once cells are 
obtained from a donor, they must be stored in specialized banks 
and both “scaled-up” (increasing batch size) and “scaled out” 
(increasing number of batches). There are several challenges 
in mass production alone including the monitoring of product 
yield and ensuring purity, potency, and viability throughout the 
process. Mass production of autologous tissue requires a facility 
allowing multiple, parallel, patient-specific production lines. 
Where scaffolds are required, testing and maintenance of quality 
attributes needs to be undertaken prior to seeding (78). Additional 
challenges include storage/transportation, contamination, and 
obtaining regulatory approval.
The long-term safety, efficacy, and functionality of the prod-
ucts also need to be closely assessed (79). Practical considerations 
that need to be contemplated include the storage environment 
and shelf life of the manufactured products.
It is also of interest that tissue-engineered products do not 
easily conform to either of the traditional Food and Drug 
Administration classification: biologics or devices (80, 81). 
Combined scaffold and cell-containing devices may be in 
more than one classification category. For devices, a single 
confirmatory study is often sufficient for FDA approval. If the 
product is regulated as a biologic, it must be reviewed and 
approved by the FDA Center for Biologics Evaluation and 
Research. If regulated as a drug, several further phases are 
required prior to FDA approval. Although these regulatory 
processes above present significant challenges, many countries 
do have streamlined regulatory processes that might reduce 
the obstacles faced (82).
TiSSUe eNgiNeeRiNg—wHeRe  
ARe we NOw?
Stable and physiologically relevant (74) tissue replacement with 
composite engineered tissue remains elusive. Allograft transplan-
tation has been an exciting development for the reconstructive 
surgeon, but the requirement for long-term immunosuppressive 
therapy (83), health-care infrastructure, and funding streams 
means it is not mainstream practice (Table 3). Tissue engineering 
is a promising alternative and has yielded small successes so far. 
Atala et al. were the first to report tissue-engineered constructs 
being used in patients (84). This was followed by several reports 
between 2008 and 2014 in a range of tissues including the trachea 
(85, 86), urethra (87), and nasal cartilage (88). Results have 
been varied; tracheal work is currently under investigation due 
to the deaths of three out of six patients and for nasal cartilage 
in particular, there was a question mark whether the tissue was 
replaced by scar or native tissue (89). The current significant 
barriers to translation for large-volume tissue replacement are 
the inability to produce “physiologicallty relevant tissue” (74) 
and difficulties with vascularization (24). Small constructs 
may succeed based on local angiogenesis (84, 87); however, 
the metabolic needs of the implanted cells in larger constructs 
means prevascularisation or the use of vascular pedicles is likely 
to be necessary (87).
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CONClUSiON AND FUTURe 
PeRSPeCTiveS
Surgical reconstruction using bioengineered tissues has the 
potential to revolutionize clinical practice. To be successful, 
one must be able to generate tissue constructs in  vitro that 
are morphologically and functionally similar to native tissues. 
There has been a steady increase in basic science activity in cell 
therapy and a growing portfolio of cell therapy trials; however, 
this has not translated to commercial products available for 
clinical use. To achieve clinical translation, a multidisciplinary 
approach that successfully integrates engineering and biological 
methodologies is necessary. Ethical, regulatory, financial, and 
clinical considerations all present challenges in the translation of 
tissue-engineered constructs from the laboratory to mainstream 
clinical practice. Even though The Medical Research Council 
states that regenerative medicine and tissue engineering “holds 
the promise of revolutionizing patient care in the 21st century” 
(91) and that stem cell therapy is viewed as a future “game 
changer” by the plastic surgery community (92), many are yet 
to be convinced of this potential within the NHS, with major 
concerns involving cost-effectiveness, efficacy, reimbursement, 
and regulation (93). There is little doubt that tissue engineering 
offers great potential to reduce patient morbidity and mortality, 
and only co-ordinated and prolonged liaison between clinicians, 
scientists, and industry will move this from potential to reality.
glOSSARY
Cell biology
Differentiation—The process by which a cell becomes special-
ized in order to perform a specific function.
Commitment—When a cell becomes dedicated to a specific 
lineage.
Potency—The array of commitment opportunities available 
to a cell.
Totipotent—Cells capable of differentiating into any body cell 
type in addition to extraembryonic or placental cells.
Multipotent—Cells capable of differentiating into multiple 
cell types along one lineage (e.g., hematopoietic stem cells).
Pluripotent—Cells that may differentiate into tissues derived 
from all three germ cell layers.
Unipotent—Cells only capable of differentiating into one cell 
type (e.g., spermatogonial stem cells).
Clonal—A population of identical cells derived from the same 
cell.
Polyclonal—A population of cells derived from multiple 
clones.
Progenitor—A cell that has limited potency, but is able to 
differentiate to another cell type, or differentiate to its target cell 
lineage.
Embryonic stem cells—Embryonically derived pluripotent 
cells that are obtained from the inner cell mass.
Induced pluripotent stem cells—Differentiated cells that are 
reverted to their pluripotent state via a set of transcription factors.
Autologous—Cells or tissues obtained from the same 
individual.
Allogeneic—Cells or tissues obtained from a different indi-
vidual of the same species.
Xenogeneic—Cells or tissues obtained from a different species.
Extracellular matrix—Biomolecules synthesized by the cell 
to provide a suitable environment to support surrounding cells 
and maintain tissue integrity in response to biochemical and 
mechanical cues.
biomaterials/Scaffolds
Scaffold—A 3D biomaterial construct that defines the geometry 
of the replacement tissue and provides environmental cues that 
promote tissue regeneration.
Biomimetic—Human-made substances, e.g., scaffolds that 
imitate nature.
Functionalization—The modification of scaffolds with bioac-
tive material to enhance the biocompatibility of the scaffold.
Nanotechnology—Technology that deals with dimensions 
and tolerances of less than 100 nm, especially the manipulation 
of individual atoms and molecules.
Biomolecular factors—Biomolecular factors include growth 
factors, transcription factors, and components of the extracellular 
matrix.
Mechanical factors—External environmental stimuli such as 
forces generated during everyday movement.
Manufacturing
Bioprinting—the process of generating spatially controlled cell 
patterns using 3D printing technologies.
Bioreactor—System in which conditions are closely con-
trolled to permit or induce certain behavior in living cells or 
tissues.
Good Laboratory Practice (GLP)—System of management 
controls for laboratories conducting research to ensure consist-
ency, reliability, reproducibility, and high quality of chemical 
(including pharmaceutical) tests.
Good Manufacturing Practice (GMP) guidelines—
Regulatory guidelines that outline specific requirements for the 
handling and processing of human tissue, ensuring safe products 
of reliable quality.
Scale-out—Increasing the number of batches of an engineered 
product.
Scale-up—Increasing batch size on an engineered product.
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